Em P Richard Clark MA, MD, MRCP, FRCPath

Professor of Haematology Molecular & Clinical Cancer Medicine

    Research

    Research Interest 1

    1) Mechanism of resistance to imatinib. Imatinib is an effective drug in CML, but is not always successful. We are currently studying the protein phosphatase 2A and its associated proteins.

    2) Clinical trial and laboratory investigations of the 2nd and 3rd generation tyrosine kinase inhibitors nilotinib, dasatinib, bosutinib and ponatinib.

    Research Group Membership

    Research Grants

    Reversal of FLT3-ITD mutations in acute myeloid leukaemia and its effect on chemotherapy resistance

    NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH - NWCR (UK)

    April 2017 - January 2021

    A Phase I/II trial of peptide vaccination in Chronic Myeloid Leukaemia (EPIC). HLA-A3 and HLA-B8

    LEUKAEMIA RESEARCH FUND

    September 2003 - February 2009

    EUTOS - European Treatment and Outcome Study for CML

    UNIVERSITY OF HEIDELBERG (GERMANY)

    June 2009 - May 2015

    A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR.

    MEDICAL RESEARCH COUNCIL (MRC)

    January 2010 - December 2012

    FSF funding to provide interim support leukaemia trials group

    ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

    March 2012 - September 2012

    The role of transporter proteins in the efficacy of imatinib and newer tyrosine kinase inhibitors in chronic myeloid leukaemia.

    KAY KENDALL LEUKAEMIA FUND (UK), ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

    June 2008 - June 2013

    Tyrosine kinase inhibitor resistance in chronic myeloid leukaemia.

    ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

    June 2006 - May 2008

    P-glycoprotein and efficacy of imatinib (Glivec).

    ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

    June 2002 - October 2003

    De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia

    UNIVERSITY OF NEWCASTLE UPON TYNE (UK)

    July 2013 - June 2018

    Support for laboratory consequences of Chronic Myeloid Leukaemia clinical work

    ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

    August 2013 - December 2019

    Do transporter proteins contribute to clinical resistance to imatinib in chronic myeloid leukaemia? A combined study in Liverpool and Glasgow, correlating transporter expression and function with imatinib uptake and efflux.

    LEUKAEMIA RESEARCH FUND

    August 2004 - June 2008

    An investigation of the mechanism of CpG oligodeoxynucleotide 5-mer-induced apoptosis/cell cycle arrest and of the relevance of c-myc gene expression in chronic myeloid leukaemia.

    LEUKAEMIA RESEARCH FUND

    December 2000 - November 2003

    Continuation of EPIC study in CML patients.

    LEUKAEMIA RESEARCH FUND

    September 2006 - May 2009

    Therapy Acceleration Programme

    BLOODWISE (UK)

    February 2012 - December 2016

    Collaboration on SPIRIT 2 project in chronic myeloid leukaemia

    UNIVERSITY OF NEWCASTLE UPON TYNE (UK)

    November 2012 - March 2013

    DESTINY: a trial of de-escalation and stopping treatment in CML patients with excellent responses to tyrosine kinase inhibitor therapy

    BLOODWISE (UK)

    June 2013 - June 2018

    An investigation of the mechanism of CpG oligodeoxynucleotide 5-mer-induced cell cycle arrest in chronic myeloid leukaemia.

    LEUKAEMIA RESEARCH FUND

    December 2003 - November 2004

    Research Collaborations

    Dr RE Clark

    Internal

    immune response to leukaemic fusion proteins